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Abstract 39 
It remains unclear in adult acute myeloid leukemia (AML) whether leukemic expression 40 
levels of CD33, the target antigen for Gemtuzumab Ozogamicin (GO), add prognostic 41 
information on GO effectiveness at different doses. CD33 expression quantified in 1583 42 
patients recruited to UK-NCRI-AML17 (younger adults) and UK-NCRI-AML16 (older 43 
adults) trials was correlated with clinical outcomes and benefit from GO including a dose 44 
randomisation. CD33 expression associated with genetic subgroups, including lower levels in 45 
both adverse karyotype and core-binding factor (CBF)-AML, but was not independently 46 
prognostic. When comparing GO versus no GO (n=393, CBF-AMLs excluded) by stratified 47 
subgroup-adjusted analysis, patients with lowest quartile (Q1) %CD33-positivity had no 48 
benefit from GO (relapse risk, HR 2·41[1·274·56], p=0·009 for trend; overall survival, HR 49 
1·52[0·922·52]). However from the dose randomisation (NCRI-AML17, n=464, CBF-50 
AMLs included), 6mg/m2 GO only had a relapse benefit without increased early mortality in 51 
CD33-low (Q1) patients (relapse risk HR 0·64[0·361·12] versus 1.70[0.99-2.92] for CD33-52 
high, p=0·007 for trend). Thus CD33 expression is a predictive factor for GO effect in adult 53 
AML; although GO does not appear to benefit the non-CBF AML patients with lowest CD33 54 
expression a higher GO dose may be more effective for CD33-low but not CD33-high 55 
younger adults. 56 
  57 
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Introduction 58 
The modest improvement with conventional cytotoxic therapies in the majority of acute 59 
myeloid leukemia (AML) patients provides an opportunity for immunotherapeutic strategies 60 
for treating this disease. Expression of CD33 is a feature of most AMLs and has been 61 
exploited for immuno-targeting using gemtuzumab ozogamicin (GO), a CD33-directed 62 
antibody-drug conjugate (ADC) that has served as a paradigm for antigen-specific 63 
immunotherapy of cancer.
1
 When combined with intensive chemotherapy GO significantly 64 
improves outcomes in newly diagnosed adult AML,
2-6
 and studies demonstrate the 65 
importance of appropriately defining patient subgroups that may most benefit from this 66 
therapy. A meta-analysis of 3325 adult patients, who did not require to be CD33 positive, in 5 67 
randomised controlled trials of GO combined with intensive chemotherapy, showed that GO 68 
significantly reduced relapse risk and improved overall survival.
7
 The greatest benefit was 69 
observed in patients with favourable-risk cytogenetics although significant benefit was also 70 
observed for intermediate-risk patients. No benefit was observed from the addition of GO in 71 
patients with adverse-risk disease. The meta-analysis appeared to show equivalent outcomes 72 
in all genetic subgroups from the lower dosage of GO compared to the higher dose with 73 
single dose schedules. This GO-derived reduced relapse risk is also observed when added to 74 
intensive chemotherapy in pediatric AML
8
 though associations with risk group are less clear 75 
in these patients.  76 
A key parameter for the potential efficacy of an ADC may be expression levels of the 77 
targeted antigen on leukemic cells as this will determine how much of the conjugate will 78 
bind. In AML, CD33 blast expression is heterogeneous between patients but there has been 79 
uncertainty of the clinical importance of this for GO effectiveness since CD33 expression 80 
levels are associated with established prognostic factors including genetic subgroups. Higher 81 
CD33 expression is a feature of patients with FLT3-ITD mutation or NPM1 mutation,
9-12
82 
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while low CD33 expression is characteristic of core-binding factor (CBF) -AML in pediatric 83 
patients 
9,11
 although, perhaps paradoxically, the CBF-AML subgroup derived the most 84 
benefit from GO in adult trials. Furthermore CD33 expression level may potentially be a 85 
prognostic factor independently of these genetic associations as observed in pediatric AML.
11
86 
Results from the Childrens Oncology Group (COG) AML trials showed that benefit from 87 
GO at a single dose of 3mg/m
2 
at first induction and then intensification 
9 
was restricted to 88 
pediatric patients with high CD33 blast expression; this was also true for CBF-AMLs. High 89 
CD33 also correlated with response to GO in the French ALFA-0701 older adult cohort in 90 
which a higher cumulative dose of GO at induction (sequential schedule of 3mg/m
2
) was 91 
administered with standard chemotherapy.
10
 Notwithstanding these data it remains unclear 92 
whether CD33 expression levels are independently predictive of GO benefit in adults and 93 
how this might compare at different doses of GO.  94 
The most recent UK- National Cancer Research Institute (NCRI) -AML trials of younger 95 
(NCRI-AML17) and older (NCRI-AML16) adult patients included standard induction 96 
chemotherapy randomised with or without a single dose of GO, a GO dose randomisation 97 
(NCR-AML17 only) and an assessment of CD33 expression by AML blasts in the pre-98 
treatment sample. We thus performed a retrospective analysis of CD33 expression on the GO 99 
treatment effect in a large cohort of these patients 100 
101 
Methods 102 
Study Cohort 103 
The NCRI-AML16 (ISRCTN11036523) and NCRI-AML17 (ISRCTN55675535) trials 104 
enrolled patients with AML (de novo or secondary) or high-risk myelodysplastic syndrome 105 
(MDS); patients were mostly aged ≥60 years in NCRI-AML16 and mostly aged <60 years 106 
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old in NCRI-AML17 (protocols in supplementary information; Figures S1-S2). In both trials 107 
CD33-positivity was not an entry requirement and patients were randomised into intensive 108 
chemotherapy arms with or without a single dose of GO in course 1 of induction. In NCRI-109 
AML16 GO was given at 3mg/m
2
, while in NCRI-AML17 patients were randomised to 110 
receive either 3mg/m
2
 or 6mg/m
2
 of GO. Trials were conducted in accordance with the 111 
Declaration of Helsinki and both institutional and research ethics committee approvals were 112 
obtained. Data regarding chemotherapy interventions
13
 and dose comparisons
14
 are published 113 
separately. Acute promyelocytic leukemia (APML) patients and patients <16 years were 114 
excluded from this analysis. 115 
Flow cytometric assessment of CD33 expression 116 
CD33 expression of AML blasts from 1583 pre-treatment BM/PB samples of non-APML 117 
patients (NCRI-AML16, n=334; NCRI-AML17, n=1249, patient deployment shown in 118 
Figure 1) was prospectively determined by multiparameter flow cytometry (MFC). Staining 119 
and data acquisition were performed by three national reference flow cytometric laboratories 120 
sharing standard operating procedures,
14
 and then centrally analysed for CD33 blast 121 
expression levels without knowledge of other clinical data for retrospective correlation with 122 
clinical characteristics and outcome.  123 
AML blast CD33 levels were measured both by median fluorescence intensity of CD33 124 
(CD33-MFI) and also as percentage (%) CD33-positivity (gating described in supplemental 125 
methods). CD33-MFI was also measured for the immunophenotypically immature 126 
CD34
+
CD38
low
 stem/progenitor cell (SPC) population when present. The CD33-MFI values 127 
in each patient were standardized using the CD33-MFI values of lymphocytes (uniformly 128 
CD33 negative) present within the same sample. %CD33-positivity was also determined 129 
using lymphocytes in each sample; blast cells with CD33 expression equivalent to 130 
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lymphocytes were classed as CD33
−
and blasts with higher expression were classed as CD33
+
131 
(Figure S3). A broad range of CD33-MFI and %CD33-positivity values were observed and so 132 
patients were grouped into quartiles (Q1, Q2, Q3, Q4) for both type of measurements.  133 
134 
Statistical methods  135 
Clinical outcome data up to March 2015 for patients enrolled on NCRI-AML16 and NCRI-136 
AML17 were analysed with median follow up of 40.7 months (range 1·271·4 months) 137 
(AML16 41·8 months (1·367·4), AML17 39·7 months (1·271·4)). Endpoint definitions are 138 
as described by Cheson with the exception that we report here overall response rate (ORR; 139 
CR+CRi, i.e. recovery is not required).
15
 Demographic data were compared using the 140 
Wilcoxon rank-sum/Kruskal Wallis test or Spearmans correlation, or chi-squared/Mantel-141 
Haenszel test for the dichotomous outcome of CD33
−
 or CD33
+
. Agreement between local 142 
and central measurement of CD33 was performed using Bland-Altman plots. Univariate 143 
analyses of time to event outcomes were performed using the logrank test; multivariable 144 
adjusted analyses were performed using Cox regression. Analysis of the effect of GO 145 
treatment was performed stratified by trial as the randomisation was 1:1 in AML16 and 2:1 in 146 
AML17, and data displayed using Forest plots. In all cases, estimates of odds/hazard rations 147 
(OR/HR) are given with 95% confidence intervals. Analyses were performed using SAS 148 
version 9.3.  149 
150 
Results 151 
CD33 expression levels and correlations with disease characteristics 152 
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Patients from the two trials were divided into quartiles based on CD33-MFI (inter-quartile 153 
cut-points; 3·52, 8·71, 19·66) or quartiles based on %CD33-positivity of the total blast 154 
population (inter-quartile cut-points; 37·1%, 75·8%, 94·9%). A non-linear correlation 155 
between these two parameters was observed and overlap of quartiles (Figure S4). There was 156 
poor agreement between our %CD33-positivity data (acquired by the reference laboratories 157 
and centrally analysed) and that entered into trial database by local laboratories (Figure S5).  158 
Disease characteristics were then assessed across the CD33 quartiles. Cytogenetic data was 159 
available for 1454 of 1583 patients (92%). Corroborating the published data, CBF-AML was 160 
found to be inversely correlated with CD33 expression across the quartiles (p<0·0001, Figure 161 
2a-b; Table 1). However, in this adult cohort adverse-risk disease was also associated with 162 
lower CD33 expression (p<0·0001, Figure 2a-b). Intermediate-risk cytogenetics significantly 163 
increased in prevalence with increasing CD33 quartile (p<0·0001, Figure 2a-b). While FLT3-164 
ITD and NPM1 mutations increased in prevalence with increasing CD33 expression 165 
(p<0·0001, Figure 2c-d; Table 1), as already reported,
9-11
 intermediate-risk patients lacking 166 
these mutations were inversely associated with CD33 levels. All the above correlations were 167 
observed using either CD33-MFI or %CD33-positivity as the assessment variable. 168 
In addition to total AML blasts, we also assessed CD33 expression in immunophenotypically 169 
immature CD34
+
CD38low blasts, which are enriched for chemo-resistant leukemic stem-cell 170 
(LSC) like populations in some patients. This analysis was performed on all patients with 171 
detectable CD34
+
CD38
low
 blasts (n=1301), and then focussed on patients with significantly 172 
expanded CD34
+
CD38
low
 blasts (n=779) using a threshold of greater than 0·35% of total 173 
WBC (>2SD above mean normal frequency) to exclude patients with immature blasts that 174 
may be predominantly non-leukemic. As with total blasts there was considerable variation in 175 
CD33 levels on immature blasts across the cohort (Table S1). We classified patients with 176 
expanded CD34
+
CD38
low
 cells into CD33
−
 (Q1) and CD33
+
 (Q2-Q4), under the supposition 177 
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that CD33
−
 cells represent a GO-unresponsive subpopulation, and thus may have prognostic 178 
value. Comparison between patient sub-groups showed that expanded CD34
+
CD38
low
 blasts 179 
in CBF-AMLs were almost always CD33
+
 (in Q2-Q4), while in both intermediate-risk and 180 
adverse-risk patients the CD34
+
CD38
low
 blasts were more heterogeneous, containing 181 
significant numbers of CD33
−
cells (Q1) (Figure 2c). Patients with CD33
+
 CD34
+
CD38
low
182 
blasts showed greater prevalence of FLT3-ITD mutation (16% vs 7%, p=0·03) and NPM1183 
mutation (12% vs 6%, p=0·1) (Table S1). 184 
185 
CD33 expression levels and clinical outcomes 186 
In an analysis adjusted for trial, there was no significant difference in outcomes between 187 
patients with and without CD33 data (p=0·4). Higher CD33 expression levels, by either 188 
measurement, showed significant positive prognostic value in univariate analyses for both 189 
overall survival (OS) and cumulative incidence of relapse (CIR) (Table 2). This did not 190 
remain significant, however, after adjustment in multivariable analysis for cytogenetics, age, 191 
log-WBC, performance status, FLT3-ITD mutation, NPM1 mutation, secondary disease and 192 
trial protocol, (OS; HR 1·01 [0·931·09], p=0·8 using CD33-MFI and HR 1·01 [0·941·09], 193 
p=0·8 using % CD33-positivity, CIR; HR 0·99 [0·911·08], p=0·8 using CD33-MFI and HR 194 
1·00 [0·911·09], p=0·9 using %CD33-positivity, Table 2). Therefore, in contrast to pediatric 195 
AML, CD33 expression on blasts is not independently prognostic for outcomes in our adult 196 
cohort. In NCRI-AML17 all CBF-AML patients received GO during induction. There was no 197 
evidence of a significant association between CD33 expression quartiles and outcomes in this 198 
subgroup (Figure S6), suggesting that other biological factors are important. Perhaps 199 
surprisingly patients with expanded CD34
+
CD38
low
 blasts that were CD33
−
 had a 200 
significantly improved OS (HR 0·61 [0·450·84] p=0·002; Table S2).  201 
Page 10 of 21
202 
CD33 expression and impact on GO-sensitivity 203 
We then asked whether CD33 expression levels were relevant to benefit in outcomes 204 
observed in patients receiving GO with their induction chemotherapy compared with patients 205 
receiving chemotherapy alone (GO vs no GO). 393 patients across the two trials were 206 
assessable for this GO vs no GO comparison with CBF-AMLs excluded as these were all 207 
given GO in AML17 and there were only two CBF-AMLs in AML16. A total of 244 patients 208 
received GO (AML16 n=42, all allocated 3mg/m
2
, AML17 n=202 at either 3mg/m
2
 (n=100) 209 
or 6mg/m
2 
(n=102); Figure 1) (In AML17, patients receiving DA were not randomised 210 
between GO and no GO  all received GO at either 3mg/m
2
 or 6mg/m
2
). The results showed 211 
no evidence of significant interaction between GO and CD33 quartiles on survival, using 212 
either CD33 parameter (Figure 3a). When evaluating relapse, however, there was a 213 
significant interaction between GO and %CD33-positive blasts (p=0·009 for trend). Patients 214 
with the lowest %CD33-positive blasts (Q1) had a significantly greater relapse risk when 215 
given GO (HR 2·41 [1·274·56]) while patients with the highest %CD33-positive blasts (Q4) 216 
showed reduced relapse risk (HR 0·63 [0·351·12]) (Figure 3b). This differential benefit was 217 
not observed using blast CD33-MFI (Figure 3b). 218 
 Having established CD33 expression was relevant to effect of GO on relapse, we then 219 
assessed for difference in outcomes by CD33 expression in 464 patients entering the AML17 220 
GO dose randomisation (3mg/m
2
, n=239; 6mg/m
2
, n=225; Figure 1). Stratification of patients 221 
by CD33 expression quartiles showed a differential benefit by GO dose for relapse (Figure 222 
4a) but not for OS (Figure 4b). Using %CD33-positivity, patients with lowest CD33 223 
expression (Q1) had most benefit from the higher 6mg/m
2
 dose of GO (p=0·007 for trend) 224 
(Figure 4a). Importantly, there was no excess early (60-day) mortality from the 6mg/m
2
 dose 225 
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in these patients (Figure 4c). Patients with the highest %CD33-positive blast levels (Q4) did 226 
not benefit from the higher dose (relapse, HR 1·70 [0·992·92]) (Figure 4a).  227 
As expanded CD34
+
CD38
low
 blasts in CBF-AMLs were almost always CD33
+
, we 228 
hypothesized this might contribute to greater GO efficacy in CBF-AMLs as clearance of 229 
potential LSCs in the CD34
+
CD38
low 
subset by GO would not be limited by their low CD33 230 
expression. An exploratory subgroup analysis of non-CBF AML patients in the GO versus no 231 
GO and GO dose randomisations did not show a significant interaction between GO 232 
treatments and CD33
+
 versus CD33
−
 expanded CD34
+
CD38
low
 blasts (Figure S7).  233 
234 
Discussion 235 
In this report, we assessed the importance of CD33 expression levels in a large cohort of 236 
adult AML patients that included randomisations to receive standard chemotherapy alone or 237 
in combination with a single dose of GO at 3mg/m
2
 or 6mg/m
2
. 238 
Greater efficacy of GO in patients with higher levels of the target antigen is logical and 239 
supported by in vitro data showing a direct relationship between CD33 expression and GO-240 
sensitivity,
16
 and clinical data from GO monotherapy in relapsed AML patients
17
 and older 241 
patients deemed unfit for intensive chemotherapy.
18
 Very recent data has emerged from the 242 
COG and French ALFA trials that pediatric and older (50-70 years) AML patients with lower 243 
CD33 expression do not benefit from the addition of GO to standard chemotherapy (3mg/m
2 
244 
single dose at induction I and intensification II in COG trial, 3mg/m
2 
fractionated doses at 245 
induction I plus single dose at consolidation for ALFA-0701).
9-10 
In these studies CD33 levels 246 
were measured using % positivity and MFI respectively. We assessed CD33 using both types 247 
of measurement sub-divided by quartiles rather than a single threshold value in order to 248 
evaluate prognostic and response correlations for the range of blast CD33 expression. 249 
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Interestingly our non-linear concordance profile of these measurements (Figure S2) is similar 250 
to that of the ALFA group
10
 despite the inevitable differences of instrumentation as well as 251 
reagents and blast gating between studies. This further validates these CD33 biomarker 252 
assays as reproducible and practical in different centers but also shows that CD33MFI and 253 
%CD33-positivity are not equivalent for some patients since higher %CD33 values are 254 
included in CD33-MFI lower quartiles. Notwithstanding we observed similar associations for 255 
both expression parameters with patient disease characteristics such as cytogenetics and 256 
molecular aberrations (FLT3-ITD and NPM1 mutations). From our adult cohort adverse 257 
karyotype, wild type FLT3 / NPM1 as well as CBF-AML are all associated with lower CD33 258 
expression. We also demonstrate an independent correlation between %CD33-positivity and 259 
GO benefit for younger and older adults with non-CBF AML.  260 
The recent COG data similarly describes an association between CD33 expression (by a 261 
different CD33-MFI assay) and GO response in their pediatric AAMLL0531 cohort 
9
 that 262 
included ~25% CBF AMLs. It appears that there was a relatively higher frequency of CBF-263 
AMLs with low CD33 expression (~45% of CBFs in Q1) enrolled in their trial than in our 264 
adult cohort (~29% of CBFs in Q1, Table 1). Since CD33-low patients derive the least 265 
benefit from GO, this may plausibly contribute to why the significant association of GO 266 
benefit with CBF-AML reported from adult studies has not been demonstrated for this COG 267 
cohort.
8
268 
In this study all CBF-AML patients included in the analysis received GO (3mg/m
2 
or 269 
6mg/m
2
) at induction, thus excluding an analysis of GO versus no GO stratified by CD33 270 
expression quartiles. There was however no significant correlation between CBF CD33 271 
expression and outcome suggesting that other factors are also important for the relative GO 272 
sensitivity of this subgroup in adults. 273 
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Our analysis also defined CD33 levels in the immunophenotypically immature 274 
CD34
+
CD38
low
 blast population, which is often expanded in AML and reported as clinically 275 
and experimentally relevant for treatment responses.
19-21
 Previous data have shown that high 276 
CD33 expression by such cells enhances their GO sensitivity.
22
 Interestingly, expanded 277 
immature blasts in CBF-AMLs were almost exclusively CD33
+
 despite lower CD33 278 
expression of the global blast population. Conversely, there was variable CD33 expression on 279 
expanded CD34
+
CD38
low
 blasts in intermediate-risk and adverse-risk patients. CD33-280 
positivity of this candidate LSC- enriched population may allow effective antigen-specific 281 
targeting and clearance of potentially more chemo-resistant subpopulations in CBF-AMLs. 282 
Our results however did not show a significant interaction between CD33 status of expanded 283 
CD34
+
CD38
low
 blasts in non-CBF AML patients and GO response. This is not unexpected 284 
due to the confounding variables of heterogeneous CD33 expression in the main blast 285 
population between patients and other biological factors for GO resistance. 286 
The clinical trials of combined chemotherapy with GO, mentioned earlier, used different 287 
doses and schedules of GO, however the meta-analysis of the individual patient data from 288 
these trials suggested a single dose of 3mg/m
2
 was as effective at preventing relapse as a 289 
6mg/m
2
 dose, while having less toxicity. The NCRI-AML17 trial included a 6mg/m
2
 vs 290 
3mg/m
2
 randomisation to ascertain whether efficacy was enhanced by the higher dose. 291 
Results overall showed no significant benefit and a higher rate of veno-occlusive disease with 292 
the higher dose although there was trend for improved outcomes in the adverse karyotype 293 
patients.
23
 Our analysis using CD33 as a stratification variable showed a significant 294 
interaction between dose and %CD33-positivity levels in NCRI-AML17 patients (younger 295 
adults); the higher 6mg/m
2
 dose of GO most improved relapse risk and was well tolerated by 296 
patients with the lowest CD33 expression levels. Conversely, patients with higher CD33 297 
levels independently of risk group do not appear to derive any additional benefit from 298 
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increasing the dose from 3mg/m
2
 to 6mg/m
2
 as single induction dose. This is the first 299 
demonstration of a pre-treatment biomarker that could inform appropriate use of a higher GO 300 
dose (and potentially other CD33-targeted antibody conjugates) at induction and suggests that 301 
the 6mg/m
2
 dose benefit for adverse-risk AML outcomes may be specific to patients with Q1-302 
CD33 expression.  303 
Further optimisation of treatment schedules in ongoing trials includes a single GO dose 304 
versus fractionated GO dose comparison (NCRI-AML18/19). Interestingly from the ALFA-305 
0701 data the fractionated GO schedule (3mg/m
2 
on day 1, maximum dose: 5mg) did not 306 
improve outcome in older adults with lower CD33 expression. This may imply that a single 307 
higher 6mg/m
2
dose is more effective than a cumulative higher dose at reducing relapse in the 308 
CD33-lower subgroup potentially since CD33 re-expression by blasts after initial exposure to 309 
GO may be even lower than pre-treatment levels. Assessment of CD33 expression will also 310 
be required in trials using next-generation CD33-directed ADC such as SGN-CD33A, 311 
reported to be more potent than GO and without liver toxicity.
24
 Ultimately, this could lead to 312 
a more personalized mode of GO treatment based on patient AML blast CD33 expression 313 
levels. 314 
315 
Supplementary information accompanies this paper on the Leukemia website 316 
317 
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Figure Legends 421 
Figure 1 422 
Outline of AML patient sample flow for CD33 assessment using pre-treatment samples from 423 
NCRI-AML16 and NCRI-AML17. CBF, core-binding factor. GO, gemtuzumab ozogamicin. 424 
425 
Figure 2 426 
AML blast CD33 expression in patient subgroups 427 
CD33 expression of pre-treatment AML blasts by normalised CD33-MFI (arbitrary units) and 428 
% positivity in cytogenetic risk groups (A) and intermediate-risk patients subdivided based 429 
on mutational (FLT3-ITD and NPM1) background (B). Expanded CD34
+
CD38
low
 blasts 430 
(when at least 0·35% of total WBC) classified as CD33
−
 (Q1 CD33-MFI) or CD33
+
 (Q2-Q4 431 
CD33-MFI) assessed in cytogenetic risk groups and mutational groups (C). 432 
433 
Figure 3 434 
Effect of CD33 expression levels on (A) overall survival and (B) relapse in GO versus no GO 435 
randomised AML patients 436 
Forest plot analysis of 393 non-CBF patients assessable for GO vs no GO comparison. 437 
Patients were stratified into CD33 expression quartile using CD33-MFI and %CD33-438 
positivity.  439 
440 
Figure 4 441 
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Effect of CD33 expression levels on (A) relapse, (B) overall survival and (C) early mortality 442 
(60 days) in patients randomised to receive 6mg/m
2
 or 3mg/m
2
 GO dose  443 
Forest plot analysis of 464 younger patients (NCRI-AML17 trial) assessable for GO vs no 444 
GO comparison. Patients were stratified into CD33 expression quartile using CD33-MFI and 445 
%CD33-positivity. 446 
Table 1: Patient demographics and CD33 expression levels by CD33 MFI and %CD33 positivity
Trial 
AML16
AML17 100 (26%) 60 (16%) 64 (17%) 75 (19%) 105 (27%) 71 (18%) 78 (20%) 80 (20%)
286 (74%) 326 (84%) 323 (83%) 311 (81%) 290 (73%) 325 (82%) 319 (80%) 315 (80%)
Randomisation† 
(AML16/AML17)
                     GO 39 (42%) 26 (33%) 33 (32%) 51 (43%) 39 (42%) 34 (34%) 36 (40%) 40 (36%)
No GO 53 (58%) 54 (68%) 69 (68%) 67 (57%) 54 (58%) 65 (66%) 55 (60%) 70 (64%)
GO dose (AML17)
 GO 3mg/m
2 41 (47%) 54 (50%) 63 (50%) 79 (56%) 54 (54%) 55 (45%) 60 (55%) 70 (53%)
GO 6mg/m
2 46 (53%) 54 (50%) 62 (50%) 62 (44%) 46 (46%) 68 (55%) 50 (45%) 61 (47%)
Age at diagnosis, y
     16-29 25 (6%) 44 (11%) 39 (10%) 41 (11%) 25 (6%) 34 (9%) 50 (13%) 41 (10%)
     30-39 25 (6%) 39 (10%) 35 (9%) 30 (8%) 28 (7%) 36 (9%) 36 (9%) 30 (8%)
     40-49 48 (12%) 75 (19%) 67 (17%) 98 (25%) 53 (13%) 73 (18%) 84 (21%) 78 (20%)
     50-59 106 (27%) 107 (28%) 127 (33%) 109 (28%) 106 (27%) 125 (32%) 105 (26%) 115 (29%)
     60-69 139 (36%) 97 (25%) 100 (26%) 82 (21%) 136 (34%) 103 (26%) 95 (24%) 106 (27%)
70+ 43 (11%) 24 (6%) 19 (5%) 26 (7%) 47 (12%) 25 (6%) 27 (7%) 25 (7%)
median (range) 59 (16-79) 54 (16-78) 54 (16-79) 52 (16-77) 59 (16-79) 54 (16-79) 52 (16-77) 54 (17-79)
Sex
Female 154 (40%) 160 (41%) 172 (44%) 201 (52%) 149 (39%) 178 (45%) 181 (46%) 192 (49%)
     Male 232 (60%) 226 (59%) 215 (56%) 185 (48%) 246 (62%) 218 (55%) 216 (54%) 203 (51%)
Diagnosis
De Novo 300 (78%) 331 (86%) 320 (83%) 344 (89%) 311 (79%) 322 (81%) 339 (85%) 352 (89%)
Secondary 49 (13%) 32 (8%) 46 (12%) 31 (8%) 50 (13%) 44 (11%) 39 (10%) 31 (8%)
MDS 37 (10%) 23 (6%) 21 (5%) 11 (3%) 34 (9%) 30 (8%) 19 (5%) 12 (3%)
WHO PS
0 250 (65%) 265 (69%) 259 (67%) 257 (67%) 264 (67%) 273 (69%) 256 (64%) 267 (68%)
1 114 (30%) 104 (27%) 111 (29%) 116 (30%) 112 (28%) 104 (27%) 121 (30%) 115 (29%)
2 17 (4%) 12 (3%) 10 (3%) 7 (2%) 14 (4%) 11 (3%) 13 (3%) 10 (3%)
3 5 (1%) 4 (1%) 7 (2%) 6 (2%) 5 (1%) 7 (2%) 7 (2%) 3 (1%)
4 0 1 (<.5%) 0 0 0 1 (<.5%) 0 0
%CD33 positivity
p-value
CD33 MFI normalised blasts
Characteristic Q1 Q2 Q3 Q4 
No of patients 386 386 387 386
Q1 Q2 Q3 Q4 p-value
395 396 397 395
0·005* 0·08*
<·0001** <·0001**
0·0004* 0·001*
0·0001* <·0001*
0·7** 0·6**
WBC count
       0-9.9 257 (67%) 198 (51%) 171 (44%) 155 (40%) 255 (65%) 218 (55%) 183 (46%) 152 (38%)
     10-49.9 93 (24%) 121 (31%) 148 (38%) 136 (35%) 94 (24%) 124 (31%) 132 (33%) 155 (39%)
     50-99.9 13 (3%) 36 (9%) 40 (11%) 53 (14%) 22 (6%) 26 (7%) 50 (13%) 48 (12%)
    100+ 23 (6%) 31 (8%) 28 (7%) 42 (11%) 24 (6%) 28 (7%) 32 (8%) 40 (10%)
Median (range) 4·9 9·2 12·8 16·4 5·1 7·2 12·7 16·6 
(0·4-430·0) (0·4-334·9) (0·6-249·0) (0·7-345·0) (0·4-430·0) (0·6-334·9) (0·7-266) (0·7-345·0)
Cytogenetics
Favourable 54 (16%) 74 (21%) 40 (11%) 18 (5%) 48 (14%) 88 (24%) 41 (11%) 10 (3%)
Intermediate 203 (59%) 219 (61%) 254 (70%) 308 (87%) 214 (61%) 211 (57%) 270 (72%) 312 (87%)
Adverse 87 (25%) 66 (18%) 71 (19%) 28 (8%) 90 (26%) 71 (19%) 62 (17%) 36 (10%)
Unknown 42 27 21 32 43 25 24 37
FLT3-ITD
WT 303 (93%) 295 (86%) 289 (81%) 235 (67%) 315 (92%) 315 (88%) 294 (82%) 230 (65%)
Mutant 22 (7%) 48 (14%) 66 (19%) 116 (33%) 27 (8%) 43 (12%) 64 (18%) 122 (35%)
Unknown 61 43 32 35 53 38 39 43
NPM1c
WT 299 (95%) 272 (80%) 231 (67%) 148 (44%) 316 (95%) 291 (83%) 220 (64%) 155 (46%)
Mutant 16 (5%) 66 (20%) 112 (33%) 188 (56%) 17 (5%) 61 (17%) 125 (36%) 185 (54%)
Unknown 71 48 44 50 62 44 52 55
ITD/NPM1c
ITD WT, NPM1c WT 281 (89%) 248 (74%) 205 (60%) 116 (35%) 295 (89%) 271 (78%) 197 (57%) 115 (34%)
ITD WT, NPM1c Mut 11 (4%) 41 (12%) 73 (21%) 110 (33%) 9 (3%) 36 (10%) 85 (25%) 109 (32%)
ITD Mut, NPM1c WT 17 (5%) 22 (7%) 26 (8%) 32 (10%) 19 (6%) 17 (5%) 23 (7%) 40 (12%)
ITD Mut, NPM1c Mut 5 (2%) 25 (7%) 39 (11%) 77 (23%) 8 (2%) 25 (7%) 40 (12%) 75 (22%)
Unknown 72 50 44 51 64 47 52 56
Post-course 1 risk score 
(AML17)
Good 50 (20%) 80 (27%) 44 (15%) 39 (13%) 47 (18%) 86 (28%) 55 (18%) 26 (9%)
Standard 88 (34%) 118 (39%) 147 (49%) 186 (62%) 91 (35%) 111 (36%) 163 (54%) 176 (59%)
Poor 118 (46%) 103 (34%) 112 (37%) 73 (25%) 118 (46%) 108 (35%) 85 (28%) 95 (32%)
<·0001** <·0001**
0·4** 0·7**
0·04** 0·2**
<·0001* <·0001*
<·0001* <·0001*
<·0001* <·0001*
*: Wilcoxon-Rank Sum/Kruskal-Wallis test; **: Spearman correlaon; : excluding CBF leukaemia (AML16 n=2, AML17 n=46); 
Abbreviations: GO=gemtuzumab ozogamicin, WHO PS=World Health Organisation performance score, WBC=white blood cell, FLT3-
ITD=FLT3 internal tandem duplication, WT=wild type; Mut=mutated, MFI=median fluorescence intensity.
Table 2: Clinical outcomes and CD33 expression
0·75 (0·66–0·85) 
p<·0001;
0·78 (0·69–0·88) 
p<·0001;
0·81 (0·68–0·96) 
p=0·02
0·86 (0·73–1·02) 
p=0·08
0·90 (0.85–0·95) 
p=0·0005;
0·90 (0·85–0·96) 
p=0·0007;
1·01 (0·93–1·09) 
p=0·8
1·01 (0·94–1·09) 
p=0·8
0·93 (0·86–0·99) 
p=0·03;
0·91 (0·85–0·98) 
p=0·01;
0·99 (0·91–1·08) 
p=0·8
1·00 (0·91–1·09) 
p=0·9
50%
35% 40% 45%
CIR 56% 54% 49% 50% 57% 55%
76% 85% 85%
50%
Q4 
OR/HR, 95% CI, p-
value 
unadjusted/adjusted
87%
OS 27% 36% 37% 48% 27%
CR/CRi 79% 80% 87% 89%
%CD33 positivity
OR/HR, 95% CI, p-
value 
unadjusted/adjusted
CD33 MFI normalised blasts
Outcome Q1 Q2 Q3 Q4 Q1 Q2 Q3 
Note: Adjusted OR/HR for age, cytogenetics, trial, log (WBC), secondary disease, ITD, NPM1. OR/HR presented 
per quartile.
Abbreviations: CR=complete remission, CRi=complete remission with incomplete blood count recovery, 
OS=overall survival, CIR=cumulative incidence of relapse, MFI=median fluorescence intensity, OR=odds ratio, 
HR=hazard ratio, CI=confidence interval.
Figure 1 
Outline of AML patient sample flow for CD33 assessment  
Poor sample with insufficient blasts 
(n=75; 5%) 
Patients with valid CD33 expression data 
(n=1583; AML16 n=334, AML17 n=1249) 
Non-APML adult patients screened for 
surface CD33 expression (n=1658) 
GO vs no GO randomisation  
AML16 & AML17 (n=393; 25%)  
(excluding CBF-AMLs) 
 no GO (n=149) 
(AML16 n=54
AML17 n=95) 
GO  (n=244) 
(AML16 n=42; all 3mg/m2) 
(AML17 n=202; 3mg/m2 n=100, 
6mg/m2 n=102) 
GO 3mg/m2
(n=239) 
GO 6mg/m2
(n=225) 
GO dose randomisation 
AML17 only (n=464; 37%) 
CBF-AMLs included 
Figure 2 
Distribution of CD33 expression with cytogenetic and mutational characteristics of AML patients  
A 
B 
C 
Figure 3:  Effect of CD33 expression levels on outcomes in GO versus no GO randomised AML patients 
Figure 3a:  Effect of GO on overall survival stratified by CD33 expression 
Figure 3b:  Effect of GO on relapse stratified by CD33 expression 
Figure 3:  Effect of CD33 expression levels on outcomes in GO versus no GO randomised AML patients 
Figure 4a:  Effect of GO dose on relapse stratified by CD33 expression 
Figure 4: Effect of CD33 expression levels on A. relapse ,  B. survival ,  C. early mortality rates ,  
in patients   randomised to receive 6mg/m2 or 3mg/m2 GO dose  
Figure 4b:  Effect of GO dose on survival stratified by CD33 expression 
Figure 4: Effect of CD33 expression levels on A. relapse ,  B. survival ,  C. early mortality rates ,  
in patients   randomised to receive 6mg/m2 or 3mg/m2 GO dose  
Figure 4: Effect of CD33 expression levels on A. relapse ,  B. survival ,  C. early mortality rates ,  
in patients   randomised to receive 6mg/m2 or 3mg/m2 GO dose  
Figure 4c:  Effect of GO dose on early mortality  stratified by CD33 expression 
